Elicio Therapeutics, Inc.
ELTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Gross Profit | -$0 | -$0 | -$0 | $0 |
| % Margin | – | – | – | 95.6% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -183.4% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -93.2% |
| EPS Diluted | -4.25 | -6.96 | -9.1 | -19.32 |
| % Growth | 38.9% | 23.5% | 52.9% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |